title: [Conformal radiotherapy of prostatic cancer: a general review].
abstract: Recent progress in radiotherapeutic management of localized prostate cancer is reviewed. Clinical aspects--including dose-effect beyond 70 Gy, relative role of conformal radiation therapy techniques and of early hormonal treatment--are discussed as well as technical components--including patient immobilization, organ motion, prostate contouring, beam arrangement, 3-D treatment planning and portal imaging. The local control and biological relapse-free survival rates appear to be improved by high dose conformal radiotherapy from 20 to 30% for patients with intermediate and high risk of relapse. A benefit of overall survival is expected but not yet demonstrated. Late reactions, especially the rectal toxicity, remain moderate despite the dose escalation. However, conformal radiotherapy demands a high precision at all steps of the procedure.
authors.affiliation: Institut Sainte-Catherine, Avignon, France.
authors.forename: B
authors.initials: B
authors.lastname: Chauvet
authors.forename: R
authors.initials: R
authors.lastname: Oozeer
authors.forename: P
authors.initials: P
authors.lastname: Bey
authors.forename: D
authors.initials: D
authors.lastname: Pontvert
authors.forename: M
authors.initials: M
authors.lastname: Bolla
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011786:Quality Control; D011829:Radiation Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D020266:Radiotherapy, Conformal; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal